Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15451459 | 1.00 | TSHR (0.45) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL12501698 | 1.00 | TSHR (0.45) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL30738812 | 0.98 | ITGB1 (0.44) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL12694405 | 0.93 | ITGB1 (0.41) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL15440085 | 0.89 | ITGB1 (0.39) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL28177284 | 0.89 | ITGB1 (0.39) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL17622156 | 0.88 | ITGB1 (0.38) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL19457185 | 0.86 | TSHR (0.41) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL10660647 | 0.85 | TSHR (0.39) | TSHRITGB1ITGA4ALDH1A1MAPK1 | |
| SCHEMBL10660652 | 0.85 | TSHR (0.39) | TSHRITGB1ITGA4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2667855-B1 | DRUG DELIVERY SYSTEMS | BIOCOMPATIBLES UK LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20140030350-A1 | Drug Delivery Systems | BIOCOMPATIBLES UK LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| EP-2667855-A1 | DRUG DELIVERY SYSTEMS | Biocompatibles Uk Ltd. (GB) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101455-A1 | DRUG DELIVERY SYSTEMS | BIOCOMPATIBLES UK LIMITED (GB) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030350-A1 | Drug Delivery Systems | FKBP2, FKBP4, HSPA9 | TSHR 1316/4885ITGB1 1148/4885ITGA4 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.